This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
bluebird bio (BLUE) 주식 개요
는 미국에서 중증 유전 질환 치료를 위한 유전자 치료제를 연구, 개발 및 상용화하는 생명공학 회사입니다. 자세히 보기
BLUE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
bluebird bio, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$4.97 |
| 52주 최고가 | US$28.60 |
| 52주 최저가 | US$3.20 |
| 베타 | 0.32 |
| 1개월 변동 | 21.81% |
| 3개월 변동 | 21.81% |
| 1년 변동 | -72.49% |
| 3년 변동 | -92.14% |
| 5년 변동 | -99.65% |
| IPO 이후 변동 | -99.08% |
최근 뉴스 및 업데이트
Seeking Alpha • May 25
High Noon For bluebird
Summary bluebird bio faces imminent bankruptcy unless a deal closes; current offer is $5 cash or $3 plus a low-value CVR. A rival bidder, Ayrmid, previously offered $4.50 plus the same CVR, but financing delays stalled a superior deal. If Ayrmid returns with a $6.50 all-cash offer before Tuesday, shareholders could see a bidding war; time is critical. At ~$5 per share, risk/reward is highly asymmetric—downside is limited, upside could be significant if a bidding war emerges. Read the full article on Seeking Alpha
새로운 내러티브 • Apr 08
Patient Starts And Capacity Expansion Will Achieve Breakeven
Sustained patient demand and operational efficiency improvements are poised to enhance revenue growth and financial stability by driving cash flow breakeven.Recent updates
Seeking Alpha • May 25
High Noon For bluebird
Summary bluebird bio faces imminent bankruptcy unless a deal closes; current offer is $5 cash or $3 plus a low-value CVR. A rival bidder, Ayrmid, previously offered $4.50 plus the same CVR, but financing delays stalled a superior deal. If Ayrmid returns with a $6.50 all-cash offer before Tuesday, shareholders could see a bidding war; time is critical. At ~$5 per share, risk/reward is highly asymmetric—downside is limited, upside could be significant if a bidding war emerges. Read the full article on Seeking Alpha새로운 내러티브 • Apr 08
Patient Starts And Capacity Expansion Will Achieve Breakeven
Sustained patient demand and operational efficiency improvements are poised to enhance revenue growth and financial stability by driving cash flow breakeven.분석 기사 • Jan 04
Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38%
bluebird bio, Inc. ( NASDAQ:BLUE ) shareholders won't be pleased to see that the share price has had a very rough...분석 기사 • Nov 15
bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 1.3x bluebird bio, Inc. ( NASDAQ:BLUE ) may be sending very bullish signals...Seeking Alpha • Sep 26
bluebird bio: Scientific Success And Financial Success, And The Gap Between
Summary Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This despite getting three gene therapies on the market. Two of bluebird bio’s gene therapies, Zentego and Lyfgenia, compete with Casgevy from Vertex Pharmaceuticals and CRISPR Therapeutics, which is approved for basically the same patient populations. The company is cutting staff, especially in R&D, in order to focus on commercial operations. But whether that will work is unknown. Read the full article on Seeking AlphaSeeking Alpha • Jun 27
bluebird bio's Flight Through Financial Fog And Fierce Rivals
Summary bluebird bio, Inc. stock plummeted by 73% amid financial struggles and operational hurdles post FDA approval of their gene therapy Lyfgenia. The company faces intense competition from CRISPR Therapeutics' Casgevy, which benefits from stronger resources and a faster market rollout. Recent financial disclosures are incomplete, obscuring a clear view of bluebird's financial health and prolonging investor uncertainty. Maintain a sell recommendation on bluebird bio due to substantial financial and operational risks, with a cautious note on potential high volatility. Read the full article on Seeking AlphaSeeking Alpha • Mar 23
bluebird bio Is Priced Below IP Value
Summary bluebird bio's stock price has dropped 64% due to safety warnings and high pricing for their sickle cell treatment. The company's intellectual property alone suggests a potential sale value of $300-320 million, higher than its current market cap of $280 million. bluebird bio has extended its cash runway and has the potential to achieve profitability within the next year. Read the full article on Seeking AlphaSeeking Alpha • Jan 25
Bluebird Bio: Innovative Therapies, Monetary Setbacks
Summary More than one year into the Launch of Zynteglo and Skysona, BLUE's sales remain underwhelming. The company launched a third gene therapy, Lyfgenia, but faces similar commercialization challenges. High treatment costs, limited patient base, outsourced production, long-term follow-up studies, and intensifying competition are all factors that obscure BLUE's path to profitability. Read the full article on Seeking Alpha분석 기사 • Oct 13
Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...분석 기사 • Jul 13
Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Oct 04
Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo
Real Endpoints said it is collaboration with bluebird bio (NASDAQ:BLUE) to provide multiple health plans with access to an outcomes-based agreement for β-thalassemia gene therapy Zynteglo through the Real Endpoints (RE) Marketplace. Zynteglo, which is approved to treat patients with beta-thalassemia who require regular blood transfusions, is priced at $2.8M for a one-time therapy, making it the most expensive treatment in history. Real noted that these plans cover ~16M people in the U.S. Through a single contract, the plans in RE Marketplace can take immediate advantage of bluebird's agreement, which offers rebates of up to 80% if treatment with Zynteglo does not enable a patient to achieve and maintain transfusion independence in two years following therapy, Real said in an Oct. 4 press release. "The plans in RE Marketplace are thrilled to be able to easily access bluebird’s innovative risk-sharing agreement, which speeds the delivery of both clinical and economic innovations," said Real's Chief Clinical Officer Jane Barlow. BLUE +2.77% to $6.30 premarketSeeking Alpha • Sep 26
Bluebird bio names interim finance chief
Gene therapy developer bluebird bio, Inc. (NASDAQ:BLUE) has named Katherine Breedis, formerly the Chief Financial Officer Consultant at Danforth Advisors, as the company’s interim Chief Financial Officer replacing the outgoing CFO Jason Cole. Ms. Breedis has also been named as BLUE’s principal financial officer and principal accounting officer, and her appointments will take effect on Oct. 14 when Mr. Cole departs. Ms. Breedis, who has worked as a CFO consultant for Danforth since Jul. 2021, served as a consultant to BLUE after the company struck a consulting agreement with the advisory firm in May. Mr. Cole’s departure came less than a month after the FDA approved BLUE’s β-thalassemia therapy Zynteglo in August, making it the priciest treatment in history at the time.Seeking Alpha • Sep 19
Bluebird bio jumps 17% on FDA approval of new gene therapy
The commercial-stage biotech bluebird bio, Inc. (NASDAQ:BLUE) added ~17% pre-market Monday after the company announced the FDA approval of its gene therapy Skysona to address the impact of a rare neurodegenerative disease called cerebral adrenoleukodystrophy (CALD). According to the late Friday press release, the drug, also known as elivaldogene autotemcel (eli-cel), will be indicated in the U.S. to slow the progression of neurologic dysfunction in boys aged 4-17 with early, active CALD. With the FDA approving Skysona under the agency’s accelerated approval pathway, BLUE has agreed to deliver long-term clinical data on the treatment to the regulator, including data from an ongoing long-term follow-up study and commercially treated patients. The company expects the drug to be commercially available by the end of 2022 at a list price of $3.0M. Concurrently, BLUE confirmed that the FDA had lifted the clinical hold on the eli-cel development program. In August, Cambridge, Massachusetts-based biotech won FDA approval for another gene therapy known as Zynteglo for β-thalassemia which it priced at $2.8M.Seeking Alpha • Sep 12
bluebird bio' chief strategy and financial officer to depart
Jason Cole, chief strategy and financial officer of bluebird bio (NASDAQ:BLUE), plans to leave the firm, effective Oct 14, 2022, to pursue new career opportunities. Mr. Cole spent 8.5 years at bluebird, serving in multiple roles including general counsel/chief legal officer, chief operating & legal officer and chief business officer. He took the chief strategy and financial officer role in Mar 2022, leading changes to stabilize the firm's financial position and strengthen its balance sheet. bluebird (BLUE) has initiated an external search for its next CFO. In the meantime, Katherine Breedis, an experienced business and financial executive from Danforth Advisors, is expected to serve as interim CFO. Cole is expected to continue to consult with the company on corporate strategy through April 2023.주주 수익률
| BLUE | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | -0.4% | 1.2% | 1.0% |
| 1Y | -72.5% | 34.9% | 28.7% |
수익률 대 산업: BLUE은 지난 1년 동안 34.9%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: BLUE은 지난 1년 동안 28.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| BLUE volatility | |
|---|---|
| BLUE Average Weekly Movement | 17.4% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: BLUE의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: BLUE의 주간 변동성은 지난 1년간 23%에서 17%로 감소했지만 여전히 US 종목의 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1992 | 248 | Andrew Obenshain | www.bluebirdbio.com |
는 미국에서 중증 유전 질환 치료를 위한 유전자 치료제를 연구, 개발 및 상용화하는 생명공학 회사입니다. 이 회사의 중증 유전 질환 치료 제품 후보로는 수혈 의존성 지중해빈혈 치료제 진테글로(ZYNTEGLO, 베티베글로겐 오토템셀), 겸상 적혈구 질환(SCD) 및 혈관 폐쇄 병력 치료제 라이프지니아(LYFGENIA, 로보티베글로겐 오토템셀), 뇌부신백질이영양증 치료제 스카이소나(SKYSONA, 엘리발도진 오토템셀) 등이 있습니다. 임상 개발 프로그램에는 SCD 환자 치료에서 로보셀의 안전성과 효능을 평가하기 위한 HGB-205, HGB-206 및 HGB-210과 지중해빈혈 환자 치료에서 베티셀의 안전성과 효능을 평가하기 위한 HGB-204, HGB-205, HGB-207 및 HGB-212가 있습니다.
bluebird bio, Inc. 기초 지표 요약
| BLUE 기초 통계 | |
|---|---|
| 시가총액 | US$48.67m |
| 순이익 (TTM) | -US$199.98m |
| 매출 (TTM) | US$103.95m |
0.5x
주가매출비율(P/S)-0.2x
주가수익비율(P/E)BLUE는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| BLUE 손익계산서 (TTM) | |
|---|---|
| 매출 | US$103.95m |
| 매출원가 | US$75.75m |
| 총이익 | US$28.19m |
| 기타 비용 | US$228.17m |
| 순이익 | -US$199.98m |
최근 보고된 실적
Mar 31, 2025
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -20.42 |
| 총이익률 | 27.12% |
| 순이익률 | -192.39% |
| 부채/자본 비율 | -175.5% |
BLUE의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2025/05/30 04:56 |
| 종가 | 2025/05/30 00:00 |
| 수익 | 2025/03/31 |
| 연간 수익 | 2024/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
bluebird bio, Inc.는 21명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Zhiqiang Shu | Berenberg |
| Vincent Chen | Bernstein |
| Matthew Luchini | BMO Capital Markets Equity Research |